Setmelanotide para obesidad

Comisión Nacional de Evaluación de Tecnologías de Salud (CONETEC) (CONETEC).
s.l; CONETEC; 9 jun. 2022.
Não convencional Espanhol | BRISA | ID: biblio-1381050

Documentos relacionados

  1. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.
  2. [Focus on obesity drug treatments].
  3. In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk.
  4. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.
  5. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
  6. Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials.
  7. Design of a novel long-acting dual GLP-1/GIP receptor agonist.
  8. Enhancement of immune responses by co-stimulation of TLR3 - TLR7 agonists as a potential therapeutics against rabies in mouse model.
  9. Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.
  10. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.